Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Rhea-AI Summary
Molecular Partners AG (MOLN) announces progress on T-cell engager MP0533 for patients with r/r AML and AML/MDS, Radio-DARPin Therapy (RDT) platform, and introduction of first program from the Switch-DARPin platform. The company also provides its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference, including clinical trial updates and future milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
-
Rhea-AI Summary
Molecular Partners AG (MOLN) and Orano Med collaborate to develop Radio-DARPin therapeutics using 212Pb radioisotope as a payload for cancer treatment. The collaboration covers multiple oncology targets, including DLL3, with anticipated first-in-human studies in 2025. Both companies will share costs for preclinical and clinical development, leveraging their unique capabilities to enable rapid clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
-
Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) to present at the 42nd Annual J.P. Morgan Healthcare Conference and upcoming investor events in Switzerland. The conference will feature presentations by the CEO and COO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
Rhea-AI Summary
Molecular Partners AG (MOLN) presents positive initial clinical data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Initial antitumor activity and acceptable safety profile observed in early dose-escalation cohorts. A previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range three. MP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed. Phase 1/2a trial remains ongoing with patients being enrolled in the fifth of seven planned dose-escalation cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) will present at the 15th Annual Protein & Antibody Engineering European Summit (PEGS Europe) to showcase the versatility of DARPin designs in conditional activation of the immune system to fight tumors. The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions, aiming to minimize damage to healthy cells. The review will include differentiated mechanisms of action such as tumor-localized activation, avidity-driven selectivity, and the novel SWITCH-DARPin approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Molecular Partners AG will present additional positive data from its Phase 1 study of MP0317 in patients with advanced solid tumors. The study shows tumor-localized CD40 activation and a favorable safety profile. Patient recruitment for the dose-escalation portion is complete, with final results expected in H1 2024. The data support further clinical evaluation of MP0317, including combination studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
Rhea-AI Summary
Molecular Partners AG will present preliminary data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data indicate an acceptable safety profile with no dose-limiting toxicity or Grade ≥3 adverse reactions. One patient in the third treatment cohort achieved a response. The study is enrolling its fifth cohort, and additional data will be presented at the ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
-
Rhea-AI Summary
Molecular Partners AG, a clinical-stage biotech company, will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3, 2023. The event will feature Patrick Amstutz, CEO, and Dr. Philippe Legenne, acting CMO. A live webcast will be available on the company's website, with a replay archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
-
Rhea-AI Summary
Molecular Partners announces corporate highlights and unaudited financial results for Q3 2023. Phase 1 dose escalation recruitment completed for MP0317 in advanced solid tumors. MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned. Radio-DARPin Therapy platform continues to progress. Company funded well into 2026 with CHF 207 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
Rhea-AI Summary
Molecular Partners announces new data from its Radio-DARPin Therapy (RDT) platform, showing increased tumor uptake and reduced accumulation in kidneys. The engineering solutions applied to optimize the RDT platform are transferrable to different tumor-associated antigens, potentially expanding the target space for radioligand therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
MOLECULAR PARTNERS AG